Santhera Secures CHF 45 Million in Funding and Announces Preliminary First Half-Year 2021 Financial Results
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Santhera will hold a conference call on Wednesday, September 22, 2021 at 14:00 CEST, 13:00 BST, 08:00 EDT. Details are at the end of this statement. Existing shareholders Idorsia, Highbridge and Waypoint Capital participate in equity raise New funding secures current operations past the NDA filing in the U.S. for vamorolone in DMD Pratteln, Switzerland, September 20, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces a strengthening of its capital structure via an oversubscribed equity financing of CHF 2
